Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease

Area of Science:

• Pediatrics
• Hematology
• Endocrinology

Background:

• Sickle cell disease (SCD) is associated with bone fragility.
• Vitamin D deficiency is a common contributing factor to bone disease in SCD patients.
• Optimal long-term vitamin D therapy for pediatric SCD bone disease remains unevaluated.

Purpose of the Study:

• To evaluate the efficacy and safety of long-term vitamin D therapy in children with SCD.
• To assess the impact of high-dose oral cholecalciferol on bone mineral density and related parameters.

Main Methods:

• A cohort of 4 children with SCD and severe vitamin D deficiency was treated.
• Monthly high-dose oral cholecalciferol was administered for 2 years.
• Bone mineral density, vitamin D levels, and markers of hyperparathyroidism were monitored.

Main Results:

• All patients showed a positive response to vitamin D therapy.
• Bone mineral density and related parameters improved with treatment.
• No cases of hypervitaminosis D or hypercalcemia were observed during the study period.

Conclusions:

• Long-term, high-dose vitamin D therapy appears safe and effective for managing bone disease in children with SCD.
• Further research is necessary to establish standardized guidelines for vitamin D dosing and toxicity prevention in this population.